Make Better Decisions

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cipla
Cerilliant
Chubb
Baxter
QuintilesIMS
US Army
Johnson and Johnson
Fuji
AstraZeneca
Covington

Generated: January 18, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,284,767

« Back to Dashboard

Which drugs does patent 6,284,767 protect, and when does it expire?

Patent 6,284,767 protects KALETRA and is included in three NDAs.

Protection for KALETRA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has sixty patent family members in twenty-three countries.
Summary for Patent: 6,284,767
Title: Retroviral protease inhibiting compounds
Abstract:A compound of the formula: ##STR1## is disclosed as an HIV protease inhibitor. Methods and compositions for inhibiting an HIV infection are also disclosed.
Inventor(s): Sham; Hing Leung (Vernon Hills, IL), Norbeck; Daniel W. (Grayslake, IL), Kempf; Dale J. (Libertyville, IL), Chen; Xiaoqi (San Mateo, CA), Betebenner; David A. (Lawrenceville, NJ), Herrin; Thomas R. (Waukegan, IL), Kumar; Gondi N. (Newbury Park, CA), Lipari; John M. (Racine, WI), Alani; Laman (Morris Plains, NJ), Ghosh; Soumojeet (Lindenhurst, IL), Gao; Rong R. (Edison, NJ), Kaul; Dilip (Edison, NJ)
Assignee: Abbott Laboratories (Abbott Park, IL)
Application Number:09/207,873
Patent Claim Types:
see list of patent claims
Use; Composition; Compound; Formulation;

Drugs Protected by US Patent 6,284,767

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Abbvie KALETRA lopinavir; ritonavir CAPSULE;ORAL 021226-001 Sep 15, 2000 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Abbvie KALETRA lopinavir; ritonavir SOLUTION;ORAL 021251-001 Sep 15, 2000 AA RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Abbvie KALETRA lopinavir; ritonavir TABLET;ORAL 021906-002 Nov 9, 2007 RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Abbvie KALETRA lopinavir; ritonavir TABLET;ORAL 021906-001 Oct 28, 2005 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 6,284,767

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,968,707 Retroviral protease inhibiting compounds ➤ Subscribe
5,914,332 Retroviral protease inhibiting compounds ➤ Subscribe
6,313,296 Retroviral protease inhibiting compounds ➤ Subscribe
7,279,582 Retroviral protease inhibiting compounds ➤ Subscribe
6,472,529 Retroviral protease inhibiting compounds ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 6,284,767

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Colombia 5070655 ➤ Subscribe
Czech Republic 293650 ➤ Subscribe
Czech Republic 9801762 ➤ Subscribe
Czech Republic 294246 ➤ Subscribe
Czech Republic 296915 ➤ Subscribe
Czech Republic 300127 ➤ Subscribe
Czech Republic 300131 ➤ Subscribe
Germany 69619140 ➤ Subscribe
Denmark 0882024 ➤ Subscribe
European Patent Office 0876353 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Covington
McKesson
UBS
Cipla
Moodys
Federal Trade Commission
Medtronic
Argus Health
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot